Summit’s pre-clinical data on its novel C. diff antibiotic, SMT19969, reinforces the potential of the antibiotic. C. diff infection is established as a major healthcare threat, with around 900,000 cases per annum in Europe and North America. Recurrent disease represents a key clinical issue with up to 30% of patients at risk of recurrent disease after the initial episode. SMT19969 has the potential to address this issue with its selective antibiotic profile and ability to leave the healthy gut m ....
